April 28, 2020 + Jessica Di Palo
5 Min read
Investment led by MTIP enables the company to expand its product development to meet the growing demand for patient-centric technology solutions in clinical trials.
MTIP is delighted to announce MTIP Fund II’s second investment in Trialbee, leading global technology provider for patient matching and engagement in clinical trials. The closure of an €11 million investment round was led by MTIP, the European specialist investor in Healthtech scale-up companies. Existing investors Industrifonden and Briban Invest also participated in the round.
The additional capital will be used to further accelerate the company’s topline growth and enhance the Trialbee technology platform, which integrates real world data and real time analytics to recruit and engange patients. This latest round brings the total amount raised by Trialbee to date to €25 million.
“We have experienced remarkable momentum over the last year and our commitment to deliver cutting-edge capabilities to our customers has contributed to this growth,” said Lollo Eriksson, CEO of Trialbee. “With this investment from MTIP, we are able to further invest in product development which will result in more value for our customers looking to accelerate and restart their global clinical trials. This partnership with MTIP speaks to the growing market opportunity and validates that Trialbee’s solutions are well-positioned to meet the demand.”
The most prescient challenges facing pharma research & development (R&D) are slow patient recruitment and large numbers of dropouts from clinical trials, causing significant delays and increasing costs for pharmaceutical products to reach the marketplace. The Trialbee solution is proven to accelerate the patient recruitment process and maintain patient engagement by incorporating data-driven digital solutions in clinical trials and optimizing protocol design and site selection.
“We are delighted to be investing in Trialbee, and look forward to working with the team to further their future growth,” commented MTIP Partner, David Germonpré. “We have looked at a lot of opportunities in this space, and believe the Company is truly differentiated in their ability to securely integrate Big Data in clinical trials. Some of the best technology solutions are built to optimize existing processes, and the Trialbee team has harnessed their knowledge from many years in the patient recruitment space to do just that.”
Trialbee is the first and only global patient recruitment and engagement company with integrated patient matching from claims data, electronic health records and digital outreach to the general public. These expanded capabilities enable Trialbee to provide additional services such as the assessment of patient feasibility, principal investigator identification and support for observational research.
The Company is proud to support their clients to optimize their clinical trials on both sides of the Atlantic, with teams in both Malmö, Sweden and Chapel Hill, North Carolina.
Dr. Christoph Kausch, Managing Partner at MTIP, commented: “Recruiting the right patients into the right clinical trial is essential for successful drug development. Traditionally, this process has been cumbersome, expensive and highly inefficient. We liked that Trialbee is really revolutionizing the patient recruitment process through deploying digital technologies that are used to source, engage and retain patients.” He concluded: “Our second Fund II investment, Trialbee, is a great example of healthcare innovation working to achieve better value for money in healthcare. By reducing the cost of development for their clients, Trialbee are also enabling more affordable and safer pharmaceuticals for the patients they affect.”
For more information please contact:
Jessica Di Palo
Head of Marketing & Communications at MTIP
Phone: +41 61 551 02 50
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
Revolutionizing medical triage with artificial intelligence
Mediktor's solution for medical triage
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
MTIP Fund II is closed!
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
New investment in Mediktor
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper